Keywords: Algeta, Alpharadin, US co-promotion, Bayer, Bone metastases, Management
Algeta takes up option to co-promote Alpharadin in the USA
Article | 13 April 2012
Norwegian cancer therapeutics developer Algeta ASA (OSE: ALGETA) says that it has exercised its option to co-promote Alpharadin (radium-223 chloride), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
